“Launching full-scale entry into the global Alzheimer’s disease treatment market”
[by Ji, Yong Jun] Curacle announced on July 23 that it has filed a PCT (Patent Cooperation Treaty) international patent for its Alzheimer's disease treatment candidate, ‘CU71 (development code).’
The PCT international patent application is a system that enables applicants to seek patent protection simultaneously in approximately 150 countries, with the option to enter the national examination stage within a maximum of 30 months from the application date. Through this filing, Curacle aims to secure global intellectual property rights for 바카라사이트 신고, targeting major countries including the United States, Europe, and Japan.
CU71 is a novel drug candidate developed as a blood-brain barrier (BBB) stabilizer, discovered through Curacle’s proprietary drug development platform, ‘SOLVADYS’. Currently in the preclinical stage, CU71 is being developed as an oral treatment.
CU71 is designed to suppress disease progression and improve cognitive function by restoring BBB dysfunction and reducing vascular leakage. The BBB functions as a protective ‘shield’ that prevents harmful external toxic substances from entering the brain. However, in Alzheimer’s patients, this barrier becomes compromised in the early stages, triggering a pathological cascade that includes amyloid beta accumulation, neuroinflammation, and neuronal damage.
Curacle has proven the therapeutic efficacy of CU71 through preclinical trials conducted on an Alzheimer’s disease animal model (5xFAD). In both the object recognition test and the Morris water maze experiment, CU71 exhibited superior effects in improving cognitive function and restoring long-term memory compared to the acetylcholinesterase inhibitor, ‘Donepezil.’
Furthermore, CU71 demonstrated improvements across key pathophysiological markers of Alzheimer’s disease. These included a reduction in amyloid beta accumulation, suppression of neuroinflammation, increased expression of vascular endothelial junction proteins such as ZO-1 and Claudin-5, and decreased expression of the receptor for advanced glycation end products (RAGE).
The preclinical results will be presented for the first time on a global academic stage at the Alzheimer’s Association International Conference (AAIC 2025), the world’s largest and most influential international forum on Alzheimer’s research, which will take place in Toronto, Canada, from July 27 to 31.
“This PCT application will serve as a foundation for strengthening the global intellectual property rights of CU71 in key markets and for initiating full-scale discussions on technology transfer and strategic collaborations,” a Curacle official said. “We anticipate that CU71’s differentiated treatment approach, targeting the BBB itself, will address the limitations of existing treatments and emerge as a novel global therapeutic alternative.”